Jump to content
ACN Latitudes Forums

cyberdog

Members
  • Content Count

    32
  • Joined

  • Last visited

  • Days Won

    1

Reputation Activity

  1. Like
    cyberdog got a reaction from Kathy4Him in possible trialing antibiotic .. excited   
    I pleaded with a family friend who's a GP that I have basically been incapacitated with treatment-resistant OCD for the past 9 years, and asked if he would trial me on an antibiotic based on information gleaned here. At first he was reluctant, but he called yesterday saying he would be willing to help me out.
     
    Unfortunately, I tend to get my hopes up extremely highly and it doesn't usually work out .. the last time was with Memantine, which turned out to be a bust.
     
    I was never tested for strep, but my OCD onset was age 19. However, I do suffer from certain immune-irregularities (IBS, chronic sinusitis). One peculiar symptom is that I've grown drastically more sensitive to medication over time, and cannot even tolerate supplements I am supposedly deficient in (Zinc, Vit D).
     
    Right now, I am torn between requesting Augmentin XR based on MomWithOCDSon's experiences and Minocycline. Both modulate glutamate. I am not aware of any formal trials on beta-lactam antibiotics in non-PANDAS OCD; however, a pilot trial is currently recruiting to test Minocycline in OCD. It also seems to be gaining valid traction as a measure for treating depression.
     
    Here is a list of properties I found that are unrelated to Minocycline's antibiotic mechanisms; I'm unaware whether Augmentin carries similar benefits:
     
    1. Is neuroprotective.
    2. Reduces brain inflammation
    3. Reduces the number of glutamate receptors.
    4. Demonstrates antidepressant properties in mouse models of depression.
    5. Is reported to act synergistically with noradrenergic antidpressants to treat depression - desipramine (but not fluoxetine).
    6. Is reported to act synergistically with NMDA antagonists.
    7. Reduces glutamate excitotoxicity by reducing the formation of quinolic acid, a NMDA agonist.
    8. Reduces mitochondrial release of cytochrome C.
    9. Modulates several signalling pathways.
    10. Reduces microglial activation.
    11. Has been reported anecdotally to successively treat depression.
    12. Reduces the expression of lipopolysaccharide-induced pro-inflammation cytokines, an effect that acts as an antidepressant in animal models.
  2. Like
    cyberdog got a reaction from MomWithOCDSon in possible trialing antibiotic .. excited   
    I pleaded with a family friend who's a GP that I have basically been incapacitated with treatment-resistant OCD for the past 9 years, and asked if he would trial me on an antibiotic based on information gleaned here. At first he was reluctant, but he called yesterday saying he would be willing to help me out.
     
    Unfortunately, I tend to get my hopes up extremely highly and it doesn't usually work out .. the last time was with Memantine, which turned out to be a bust.
     
    I was never tested for strep, but my OCD onset was age 19. However, I do suffer from certain immune-irregularities (IBS, chronic sinusitis). One peculiar symptom is that I've grown drastically more sensitive to medication over time, and cannot even tolerate supplements I am supposedly deficient in (Zinc, Vit D).
     
    Right now, I am torn between requesting Augmentin XR based on MomWithOCDSon's experiences and Minocycline. Both modulate glutamate. I am not aware of any formal trials on beta-lactam antibiotics in non-PANDAS OCD; however, a pilot trial is currently recruiting to test Minocycline in OCD. It also seems to be gaining valid traction as a measure for treating depression.
     
    Here is a list of properties I found that are unrelated to Minocycline's antibiotic mechanisms; I'm unaware whether Augmentin carries similar benefits:
     
    1. Is neuroprotective.
    2. Reduces brain inflammation
    3. Reduces the number of glutamate receptors.
    4. Demonstrates antidepressant properties in mouse models of depression.
    5. Is reported to act synergistically with noradrenergic antidpressants to treat depression - desipramine (but not fluoxetine).
    6. Is reported to act synergistically with NMDA antagonists.
    7. Reduces glutamate excitotoxicity by reducing the formation of quinolic acid, a NMDA agonist.
    8. Reduces mitochondrial release of cytochrome C.
    9. Modulates several signalling pathways.
    10. Reduces microglial activation.
    11. Has been reported anecdotally to successively treat depression.
    12. Reduces the expression of lipopolysaccharide-induced pro-inflammation cytokines, an effect that acts as an antidepressant in animal models.
×
×
  • Create New...